Bone penetration of linezolid in osteoarticular tuberculosis patients of China
Background: Linezolid presents strong antimicrobial activity against multidrug-resistant (MDR) pulmonary tuberculosis (TB), but its application in osteoarticular tuberculosis treatment remains understudied. Our objective was to analyze the bone penetration efficiency of linezolid in osteoarticular T...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-02-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971220325194 |
| _version_ | 1818966701673283584 |
|---|---|
| author | Shu’an Wen Tingting Zhang Xia Yu Weijie Dong Tinglong Lan Jun Fan Yi Xue Fen Wang Lingling Dong Shibing Qin Hairong Huang |
| author_facet | Shu’an Wen Tingting Zhang Xia Yu Weijie Dong Tinglong Lan Jun Fan Yi Xue Fen Wang Lingling Dong Shibing Qin Hairong Huang |
| author_sort | Shu’an Wen |
| collection | DOAJ |
| description | Background: Linezolid presents strong antimicrobial activity against multidrug-resistant (MDR) pulmonary tuberculosis (TB), but its application in osteoarticular tuberculosis treatment remains understudied. Our objective was to analyze the bone penetration efficiency of linezolid in osteoarticular TB patients. Methods: Osteoarticular TB patients, treated with 600 mg q 24 h linezolid-containing regimens and undergoing surgery, were prospectively and consecutively enrolled. One dose linezolid was administered before surgery. Blood and bone samples were collected simultaneously during operation, and their linezolid concentrations were then detected using high-performance liquid chromatography-tandem mass spectrometry. Pus samples were subjected to mycobacterial culture and GeneXpert MTB/RIF assay. The minimum inhibition concentrations (MICs) and drug susceptibility testing were performed with the recovered isolates. Results: A total of 36 eligible osteoarticular TB patients were enrolled, including five MDR/rifampicin-resistant cases. All the 12 recovered isolates had MICs ≤0.5 μg/mL for linezolid. Mean concentrations in plasma, collected 100−510 min after the preoperative dosing, were 10.43 ± 4.83 μg/mL (range 3.29−22.26 μg/mL), and median concentrations in bone were 3.93 μg/mL (range 0.61−16.34 μg/mL). The median bone/plasma penetration ratio was 0.42 (range 0.14−0.95 μg/mL). Linezolid concentration in bone had a linear correlation with the drug concentration in plasma (r = 0.7873, p < 0.0001), while plasma concentration could explain 61.98% of the variation of concentration in bone (R2 = 0.6198). Notably, stratification analysis by sampling time demonstrated that samples collected 200−510 min after dosing had very good linear relationships between their bone and plasma concentrations (r = 0.9323). Conclusions: Linezolid penetrates from blood to bone efficiently, and the penetration further stabilizes ∼3 h after dosing. |
| first_indexed | 2024-12-20T13:37:05Z |
| format | Article |
| id | doaj.art-0ff73e289da142e396a4e40682fa1ea0 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-20T13:37:05Z |
| publishDate | 2021-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-0ff73e289da142e396a4e40682fa1ea02022-12-21T19:38:55ZengElsevierInternational Journal of Infectious Diseases1201-97122021-02-01103364369Bone penetration of linezolid in osteoarticular tuberculosis patients of ChinaShu’an Wen0Tingting Zhang1Xia Yu2Weijie Dong3Tinglong Lan4Jun Fan5Yi Xue6Fen Wang7Lingling Dong8Shibing Qin9Hairong Huang10National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, ChinaNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, ChinaNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, ChinaDepartment of Orthopedics, Beijing Chest Hospital, Capital Medical University, Beijing, ChinaDepartment of Orthopedics, Beijing Chest Hospital, Capital Medical University, Beijing, ChinaDepartment of Orthopedics, Beijing Chest Hospital, Capital Medical University, Beijing, ChinaNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, ChinaNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, ChinaNational Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, ChinaDepartment of Orthopedics, Beijing Chest Hospital, Capital Medical University, Beijing, China; Corresponding authors.National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China; Corresponding authors.Background: Linezolid presents strong antimicrobial activity against multidrug-resistant (MDR) pulmonary tuberculosis (TB), but its application in osteoarticular tuberculosis treatment remains understudied. Our objective was to analyze the bone penetration efficiency of linezolid in osteoarticular TB patients. Methods: Osteoarticular TB patients, treated with 600 mg q 24 h linezolid-containing regimens and undergoing surgery, were prospectively and consecutively enrolled. One dose linezolid was administered before surgery. Blood and bone samples were collected simultaneously during operation, and their linezolid concentrations were then detected using high-performance liquid chromatography-tandem mass spectrometry. Pus samples were subjected to mycobacterial culture and GeneXpert MTB/RIF assay. The minimum inhibition concentrations (MICs) and drug susceptibility testing were performed with the recovered isolates. Results: A total of 36 eligible osteoarticular TB patients were enrolled, including five MDR/rifampicin-resistant cases. All the 12 recovered isolates had MICs ≤0.5 μg/mL for linezolid. Mean concentrations in plasma, collected 100−510 min after the preoperative dosing, were 10.43 ± 4.83 μg/mL (range 3.29−22.26 μg/mL), and median concentrations in bone were 3.93 μg/mL (range 0.61−16.34 μg/mL). The median bone/plasma penetration ratio was 0.42 (range 0.14−0.95 μg/mL). Linezolid concentration in bone had a linear correlation with the drug concentration in plasma (r = 0.7873, p < 0.0001), while plasma concentration could explain 61.98% of the variation of concentration in bone (R2 = 0.6198). Notably, stratification analysis by sampling time demonstrated that samples collected 200−510 min after dosing had very good linear relationships between their bone and plasma concentrations (r = 0.9323). Conclusions: Linezolid penetrates from blood to bone efficiently, and the penetration further stabilizes ∼3 h after dosing.http://www.sciencedirect.com/science/article/pii/S1201971220325194Osteoarticular tuberculosisLinezolidPlasmaBoneDrug penetration |
| spellingShingle | Shu’an Wen Tingting Zhang Xia Yu Weijie Dong Tinglong Lan Jun Fan Yi Xue Fen Wang Lingling Dong Shibing Qin Hairong Huang Bone penetration of linezolid in osteoarticular tuberculosis patients of China International Journal of Infectious Diseases Osteoarticular tuberculosis Linezolid Plasma Bone Drug penetration |
| title | Bone penetration of linezolid in osteoarticular tuberculosis patients of China |
| title_full | Bone penetration of linezolid in osteoarticular tuberculosis patients of China |
| title_fullStr | Bone penetration of linezolid in osteoarticular tuberculosis patients of China |
| title_full_unstemmed | Bone penetration of linezolid in osteoarticular tuberculosis patients of China |
| title_short | Bone penetration of linezolid in osteoarticular tuberculosis patients of China |
| title_sort | bone penetration of linezolid in osteoarticular tuberculosis patients of china |
| topic | Osteoarticular tuberculosis Linezolid Plasma Bone Drug penetration |
| url | http://www.sciencedirect.com/science/article/pii/S1201971220325194 |
| work_keys_str_mv | AT shuanwen bonepenetrationoflinezolidinosteoarticulartuberculosispatientsofchina AT tingtingzhang bonepenetrationoflinezolidinosteoarticulartuberculosispatientsofchina AT xiayu bonepenetrationoflinezolidinosteoarticulartuberculosispatientsofchina AT weijiedong bonepenetrationoflinezolidinosteoarticulartuberculosispatientsofchina AT tinglonglan bonepenetrationoflinezolidinosteoarticulartuberculosispatientsofchina AT junfan bonepenetrationoflinezolidinosteoarticulartuberculosispatientsofchina AT yixue bonepenetrationoflinezolidinosteoarticulartuberculosispatientsofchina AT fenwang bonepenetrationoflinezolidinosteoarticulartuberculosispatientsofchina AT linglingdong bonepenetrationoflinezolidinosteoarticulartuberculosispatientsofchina AT shibingqin bonepenetrationoflinezolidinosteoarticulartuberculosispatientsofchina AT haironghuang bonepenetrationoflinezolidinosteoarticulartuberculosispatientsofchina |